This is a working overview of GHRH analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
=== Urea cycle disorders === Disorders of the distal urea cycle, such as citrullinemia, argininosuccinic aciduria and argininemia are included in newborn screening programs in many jurisdictions that using tandem mass spectrometry to identify key amino acids. Proximal urea cycle defects, such as ornithine transcarbamylase deficiency and carbamoyl phosphate synthetase deficiency are not included in newborn screening panels because they are not reliably detected using current technology, and also because severely affected infants will present with clinical symptoms before newborn screening results are available. Some regions claim to screen for HHH syndrome (hyperammonemia, hyperornithinemia, homocitrullinuria) based on the detection of elevated ornithine levels in the newborn screening dried blood spot, but other sources have shown that affected individuals do not have elevated ornithine at birth.
can be interpreted as the cumulative number of diagnoses (including individuals who have recovered) or the present number of infection cases; the logarithmic growth rate is the same for either definition. In order to estimate
and he was wearing camouflage, a hunting vest and had an AR-15 strapped to his back" and that God supported Trump's plan to arm teachers. Following the death of Billy Graham on February 21, 2018, Bakker attended Graham's funeral and paid his respects, stating that Graham was the greatest preacher since Jesus, and also remarking that Graham had visited him in prison. On the Stand in the Gap Today radio program, Pennsylvania Pastors Network president Sam Rohrer criticized Bakker's civil-war prediction. Christian Today criticized Bakker's show for preying on "the most vulnerable kinds of people" and claimed that it had "no place on our TV screens."
==== Reagent coflow prior to droplet formation ==== Reagents can be added at the time of droplet formation through a "co-flow" geometry. Reagent streams are pumped in separate channels and join at the interface with a channel containing the continuous phase, which shears and creates droplets containing both reagents. By changing the flow rates in reagent channels, reagent ratios within a droplet can be controlled.
Sources: en.wikipedia.org
==== Urquía Carreño resigns ==== On August 18, 2024, a special session of more than a hundred Freemasons was called by Urquía Carreño to gather at the theatre hall of the Grand Lodge of Cuba, on the 3rd floor of the building. One Cuban Freemason told reporters that: "...he had manipulated a circus to stay in office. He's shameless, they were lies after lies; all the brothers were standing asking him to hand over the keys to his office." The people in the theatre started chanting: "Hand over and leave!" After tensions had escalated, Urquía Carreño left the theatre to go back to his office. However, the Freemasons followed him up to the eleventh floor. Urquía Carreño agreed to meet with representatives of the delegation in his office, so three men were chosen to represent them. The three men sat with three of Urquía Carreño's men, and discussed terms of negotiation, while the rest of the delegation waited in the hallway. On August 18, 2024, after two hours of negotiation, Urquía Carreño finally relented and agreed to tender his resignation. In his resignation, he said that it was: "for the good of the institution." Mayker Filema Duarte assumed the role of Acting Grand Master until an election could be held, and immediately launched a financial audit of the entire Grand Lodge. At the beginning of September, Filema Duarte accused Urquía Carreño of the theft of yet another $MN2,116,555.33, stolen sometime between January and August 2024.
A seminal work of traditional Chinese medicine was the Huangdi neijing (Yellow Emperor's Inner Canon) compiled between the 3rd and 2nd centuries BC (i.e. originating in the Warring States period), which viewed the human body, its organs and tissues through the lens of the metaphysical five phases and yin and yang, and stated a belief in two circulatory channels of qi vital energy. In surgery, Han dynasty era Chinese texts offered practical advice for certain procedures such as clinical lancing of abscesses. The first known physician in China to describe the use anesthesia for patients undergoing surgery was the Eastern Han physician Hua Tuo (d. 208 AD), who utilized his knowledge of Chinese herbology based in the Huangdi neijing to create an ointment that healed surgical wounds within a month. One of his surgical procedures was the removal of a dead fetus from the womb of a woman whom he diagnosed and cured of her ailments.
== Medical uses == Alendronatec sodium is indicated for the treatment and prevention of osteoporosis in postmenopausal women; the treatment to increase bone mass in men with osteoporosis; the treatment of glucocorticoid-induced osteoporosis; and the treatment of Paget's disease of bone.
== Membership of professional bodies == Member of the Governing Council of the Pharmacists Council of Nigeria, Nnamdi Azikiwe University Member of the Nanomedicine Society of Nigeria Member of the Global Young Academy Member of the American Society for Cell biology Member of many other professional bodies including, Institute of Public Analysts of Nigeria; West African Society for Pharmacology, Nigeria; Society for Medicinal Plant Research, Germany; Pan African Medical Mycology Society, South Africa; International Society for Anti-infective Pharmacology; Materials Society of Nigeria; and, Nigerian Society of Forensic Scientists (Pioneer member of Board of Directors)
The objective of an atomic bomb is to produce a device, according to Serber, "...in which energy is released by a fast neutron chain reaction in one or more of the materials known to show nuclear fission." According to Rhodes, "Untamped, a bomb core even as large as twice the critical mass would completely fission less than 1 percent of its nuclear material before it expanded enough to stop the chain reaction from proceeding. Tamper always increased efficiency: it reflected neutrons back into the core and its inertia...slowed the core's expansion and helped keep the core surface from blowing away." Rearrangement of the core material's subcritical components would need to proceed as fast as possible to ensure effective detonation. Additionally, a third basic component was necessary, "...an initiator—a Ra + Be source or, better, a Po + Be source, with the radium or polonium attached perhaps to one piece of the core and the beryllium to the other, to smash together and spray neutrons when the parts mated to start the chain reaction." However, any bomb would "necessitate locating, mining and processing hundreds of tons of uranium ore...", while U-235 separation or the production of Pu-239 would require additional industrial capacity.
Sources: en.wikipedia.org
=== Preclinical === AB-300 (AB300) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist AB-5006 (AX-5006) – Escherichia coli csgA protein aggregation inhibitor and gastrointestinal microbiome modulator [96] AEX-23 – orexin OX1 receptor agonist and α-synuclein aggregate/modulator [97] Afamelanotide ([Nle4,DPhe7]-α-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan; MT-I; Prenumbra; Scenesse) – melanocortin receptor agonist [98] Alpha-synuclein aggregation inhibitor (ACI-5755; morphomer α-synuclein) – α-synuclein inhibitor [99] BEBT-758 – RNA interference and α-synuclein expression inhibitor [100] Bevemipretide (SBT-272) – cardiolipin ligand and stabilizer [101] BSC-3301 – receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [102] BXQ-350 (SapC; SapC-DOPS; sphingolipid activator protein C) – sphingomyelin phosphodiesterase stimulant and sphingosine 1-phosphate stimulant [103] Cannabidiol (CBD) – cannabinoid receptor modulator and other actions [104] Carbon monoxide (CO; HBI-002) – heme oxygenase 1 modulator [105] CB-401 – amyloid β-protein modulator [106] CBT-102 – undefined mechanism of action [107] CJRB-301 (MRx-0005) – bacteria replacement and microbiome modulator [108] CJRB-302 (MRx-0029) – bacteria replacement and microbiome modulator [109] CK-0803 – regulatory T-lymphocyte replacement [110] CU-13001 – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [111] EHP-102 (VCE-003.2) – cannabinoid CB2 receptor agonist and peroxisome proliferator-activated receptor alpha (PPARα) modulator (cannabigerol (CBG) derivative) [112] Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist [113] FHL-401 – toll-like receptor 2 antagonist [114] FHL-701 – interleukin-12 (IL-12) subunit p40 inhibitor [115] FKK-01PD (FKK-01PD; TGHW-01AP; apomorphine prodrug) – non-selective dopamine receptor agonist and other actions [116] HT-4403 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [117] IC-100 (ICCN-100) – various actions [118] KFRX-05 (BK-40195) – leucine-rich repeat kinase 2 (LRRK2) inhibitor and protein tyrosine kinase inhibitor [119] KP-405 – undefined mechanism of action [120] LB-P4 – bacteria replacement and microbiome modulator [121] Mbiotix – bacteria replacement and microbiome modulator [122] ML-021 – muscarinic acetylcholine M4 receptor antagonist [123] MP-201 – 2,4-dinitrophenol (DNP) prodrug and various actions [124] NB-003 – gene transference and parkin protein replacement [125] NB-129 – undefined mechanism of action [126] NLY-02 – glial cell inhibitor [127] NLY-03 – undefined mechanism of action [128] NNI-362 – 70 kDa ribosomal protein S6 kinase modulator [129] NRG-5051 – mitochondrial permeability transition pore inhibitor [130] PMN-442 – monoclonal antibody against α-synuclein [131] PP-003 – α-synuclein degrader [132] Research programme: 3100 programme - DigmBio/Daegu Catholic University – G protein-coupled receptor (GPCR) modulators [133] Research programme: enzyme targeted therapeutics - Nitrase Therapeutics – enzyme modulators and α-synuclein inhibitors [134] Research programme: neurodegenerative disease therapeutics - Caraway Therapeutics – autophagy stimulants and MCOLN1 stimulants [135] RGL-193 – undefined mechanism of action [136] ST-502 – gene therapy and α-synuclein genetic transcription inhibitor [137] Tomaralimab (NM-101; NM-102; NM-103; OPN-305) – monoclonal antibody against toll-like receptor 2 [138] Zervimesine (CT-1812; Elayta) – sigma σ2 receptor antagonist [139]
Pediatric endocrinologists were the only physicians interested in the arcana of GH metabolism and children's growth , but their previously academic arguments took on new practical significance with major financial implications. The major scientific arguments dated back to the days of GH scarcity:
Stansbury ran unopposed in the 2018 Democratic primary for the 28th district of the New Mexico House of Representatives. In the general election, she defeated Republican incumbent Jimmie C. Hall, who had held the seat for seven terms. Stansbury was again unopposed in the 2020 primary. She defeated Republican Thomas R. Stull and Libertarian Robert Vaillancourt in the general election. In the House, Stansbury introduced legislation to improve the energy conservation and water resource management of the state of New Mexico. She served as the vice chair of the Energy, Environment, & Natural Resources Committee. Upon Stansbury's 2021 resignation from the state legislature in order to run to represent New Mexico in the U.S. House of Representatives, the Bernalillo County Commission appointed Pamelya Herndon as her replacement.
The larval brain and nerve cord consist of 3,016 neurons and 548,000 synapses. The Drosophila adult central nervous system (brain plus ventral nerve cord) has been reconstructed in both the male and the female and contains around 160,000 neurons and over 200 million synapses. These datasets allow scientists to generate testable hypotheses about how the brain processes information and gives rise to behavior.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.